Page 21 - Robert Kramer News Today

UNITED NATIONS -- The U.N. Security Council is calling for accelerated availability of...

skodonnell/iStock (WASHINGTON) -- The beleaguered biotech firm Emergent BioSolutions will face a congressional inquiry Wednesday, scrutinized for what investigators say are the "serious deficiencies" in their manufacturing that led to up to 15 million doses worth of COVID-19 vaccine ingredients being compromised and disposed of because of cross-contamination. Top Emergent executives Fuad El-Hibri, the companys f...

1 of 40 A woman takes selfie as she receives the Covishield vaccine against COVID-19 in Gauhati, Assam, India, Monday, May 17, 2021. Anupam Nath A heath worker in protective suit takes nasal swab sample of a man to test for COVID-19 in a slum area in Gauhati, Assam state, India, Monday, May 17, 2021. Anupam Nath People stand in queue to receive the Covishield vaccine against COVID-19 in Gauhati, Assam, India, Monday, May 17, 2021. Anup...

COVID deaths, cases have fallen in US Updated May 12, 2021, 1 hour ago Email to a Friend COVID-19 deaths in the United States have tumbled to an average of around 600 per day — the lowest level in 10 months — with the number of lives lost dropping to single digits in well over half the states and hitting zero on some days. Confirmed infections, meanwhile, have fallen to about 38,000 day on average, their lowest mark since mid-September. While that is still cause for concern, they hav...

© Getty Images Leaders at Emergent BioSolutions, the manufacturer whose Baltimore factory ruined millions of COVID-19 vaccine doses, are slated to testify in front of the House next week as part of an inquiry into the company.  The company’s CEO and President Robert Kramer and Executive Chairman Fuad El-Hibri agreed to appear before the Oversight and Reform Subcommittee on the Coronavirus Crisis on May 19 to address questions about the up to 15 million destroyed doses of the Johnson & Johns...

House Majority Whip James E. Clyburn, D-S.C., and Chairman of the House Select Subcommittee on the Coronavirus Crisis speaks during a hearing on Capitol Hill in Washington, Thursday, April 15, 2021, on the coronavirus crisis. (AP Photo/Susan Walsh, Pool) **FILE** more > By Tom Howell Jr. - The Washington Times - Wednesday, May 12, 2021 Executives from a company blamed for mishaps in the production ...

What happened Emergent BioSolutions (NYSE:EBS) fell 30% in April, according to data from S&P Global Market Intelligence, after quality-control errors at one of the companys facilities ruined millions of doses of Johnson & Johnsons COVID-19 vaccine. The purge was required after ingredients of another vaccine had contaminated the production area of J&Js shot.   Image source: Getty Images. So what CEO Robert Kramer chalked the errors up to the complexity of manufacturing two biologic products i...

by Paul Haeder / May 3rd, 2021 How did we ever get to this point … to the point where, as I put it in The Covidian Cult, “instead of the cult existing as an island within the dominant culture, the cult has become the dominant culture, and those of us who have not joined the cult have become the isolated islands within it?” To understand this, one needs to understand how cults control the minds of their members, because totalitarian ideological movements operate more or less the same way, ...

Canada’s regulator holds Johnson & Johnson vaccine over Emergent link. Ground crew unload a shipment of the Johnson & Johnson vaccine from South Africa at Toronto Pearson Airport in Mississauga, Ontario, Canada, on Wednesday.Credit...Carlos Osorio/Reuters April 30, 2021 Canada’s drug and vaccine regulator said on Friday that it was withholding the release of the country’s first shipment of the Johnson & Johnson vaccine to verify its safety and quality. Health Canada, the regulato...

What a decade of inspection reports shows about firm tasked with helping make vaccine Johnson & Johnson manufacturer’s embattled history with the FDA Replay Video UP NEXT Even as shots of the Johnson & Johnson COVID-19 vaccine resume across the country following a recent federally-recommended pause, new manufacturing at a key facility tasked with helping make the vaccine is still on hold. Emergent BioSolutions -- the company whose Baltimore-area plant had been developing a key component for...